Analysts Issue Forecasts for Amyris Inc’s Q1 2018 Earnings (AMRS)
Amyris Inc (NASDAQ:AMRS) – Investment analysts at B. Riley decreased their Q1 2018 earnings per share (EPS) estimates for Amyris in a research note issued to investors on Tuesday. B. Riley analyst C. Driscoll now forecasts that the biotechnology company will post earnings of ($0.38) per share for the quarter, down from their previous forecast of ($0.20). B. Riley currently has a “Buy” rating and a $10.00 price objective on the stock. B. Riley also issued estimates for Amyris’ Q2 2018 earnings at ($0.21) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at $0.17 EPS, FY2018 earnings at ($0.52) EPS, Q1 2019 earnings at ($0.12) EPS, Q2 2019 earnings at $0.00 EPS and FY2019 earnings at $0.16 EPS.
Amyris (NASDAQ:AMRS) last released its quarterly earnings results on Thursday, March 15th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.24). The company had revenue of $80.59 million for the quarter, compared to analysts’ expectations of $68.14 million. During the same period in the previous year, the business posted ($0.09) EPS. The firm’s revenue was up 262.4% on a year-over-year basis.
Shares of Amyris stock opened at $6.73 on Thursday. The company has a quick ratio of 0.82, a current ratio of 0.92 and a debt-to-equity ratio of -0.78. Amyris has a 1-year low of $1.86 and a 1-year high of $10.65.
In other news, insider John Melo sold 10,776 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $4.68, for a total transaction of $50,431.68. Following the completion of the sale, the insider now owns 83,172 shares in the company, valued at approximately $389,244.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 11.30% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Tanaka Capital Management Inc. increased its holdings in shares of Amyris by 72.0% during the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock worth $1,691,000 after buying an additional 221,295 shares during the last quarter. Hudson Bay Capital Management LP acquired a new stake in shares of Amyris during the 4th quarter worth approximately $451,000. KBC Group NV increased its holdings in shares of Amyris by 228.4% during the 3rd quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock worth $192,000 after buying an additional 41,834 shares during the last quarter. Creative Planning acquired a new stake in shares of Amyris during the 4th quarter worth approximately $188,000. Finally, Compagnie Lombard Odier SCmA boosted its position in shares of Amyris by 60.0% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 104,000 shares of the biotechnology company’s stock worth $390,000 after purchasing an additional 39,000 shares during the period. Institutional investors and hedge funds own 22.27% of the company’s stock.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.